Study of clinical experience with different approaches to controlled ovarian hyperstimulation: a focus on safety and efficacy
暂无分享,去创建一个
E. Naseva | T. Timeva | H. Lebanova | I. Getov | S. Stoev | Boyka Petkova
[1] P. Humaidan,et al. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders , 2017, Human reproduction.
[2] Y. L. Chen,et al. [A randomized, single-blind, parallel-controlled and multicentre study: compare the efficacy and safety of domestic and imported human recombinant FSH in WHO group Ⅱ anovulatory infertility]. , 2016, Zhonghua fu chan ke za zhi.
[3] Morton B. Brown,et al. Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles. , 2015, Fertility and sterility.
[4] P. Humaidan,et al. Efficacy and Safety of Pergoveris in Assisted Reproductive Technology—ESPART: rationale and design of a randomised controlled trial in poor ovarian responders undergoing IVF/ICSI treatment , 2015, BMJ Open.
[5] P. Patrizio,et al. Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century. , 2015, Human reproduction update.
[6] A. Obruca,et al. A multi-centre phase 3 study comparing efficacy and safety of Bemfola(®) versus Gonal-f(®) in women undergoing ovarian stimulation for IVF. , 2015, Reproductive biomedicine online.
[7] Seth R. Flaxman,et al. National, Regional, and Global Trends in Infertility Prevalence Since 1990: A Systematic Analysis of 277 Health Surveys , 2012, PLoS medicine.
[8] J. M. Tenías,et al. Pharmaceutical care for patients undergoing assisted reproduction techniques , 2012 .
[9] D. Ezcurra,et al. Predicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment , 2012, Reproductive Biology and Endocrinology.
[10] M. Eijkemans,et al. Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis. , 2011, Human reproduction update.
[11] N. Laufer,et al. Ovarian Hyperstimulation Syndrome: Definition, Incidence, and Classification , 2010, Seminars in reproductive medicine.
[12] C. Simón,et al. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. , 2010, Human reproduction.
[13] E. Kolibianakis,et al. Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment. , 2008, Human reproduction.
[14] G. Pennings,et al. Coming soon to your clinic: patient-friendly ART. , 2007, Human reproduction.
[15] S. Moon,et al. Comparison of the efficacy and safety of a new recombinant human follicle‐stimulating hormone (DA‐3801) with follitropin‐α (Gonal‐F®) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology , 2007, The journal of obstetrics and gynaecology research.
[16] P. Devroey,et al. Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients. , 2006, Human reproduction.
[17] S. Moon,et al. Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology. , 2007, The journal of obstetrics and gynaecology research.
[18] M. Sedler,et al. Management of ovarian hyperstimulation syndrome , 2006 .
[19] L. Natarajan,et al. The concerns during assisted reproductive technologies (CART) scale and pregnancy outcomes. , 2004, Fertility and sterility.